Association Between COVID-19 and UTIs Caused by ESBL Organism in Infants (ABCUCEOI)

Hamad Medical Corporation (HMC)

Status: Completed

Conditions: Renal Insufficiency

Treatments: Other: association; Other: assessment; Other: comparing, prevalence; Other: evaluation

Study type: Observational

Funder types: Industry

Identifiers

NCT05630326

MRC-01-22-158

Details and patient eligibility

About

Urinary tract infections (UTIs) in infants and young children are one of the most common bacterial infections, usually febrile illness without source, frequently due to Enterobacteriaceae, mainly Escherichia coli.

Multidrug-resistant organisms including extended-spectrum beta-lactamase (ESBL) producing bacteria are becoming more prevalent. Due to the risk factors of ESBL-producing organisms in community-acquired (CA)-UTIs in infants in QATAR and Arab countries are still not studied because of the limited therapeutic options. hence, the importance of this study is to get knowledge about how to decrease the rapidly increasing in ESBL- producing bacteria, in infants, and to use antibiotics in a suitable guideline.so, The aim of this retrospective case-control study is to determine the clinical manifestations, and investigations of urinary tract infections among infants and the association with COVID-19 infection, in pediatric emergency centers at Hamad General Hospital - Qatar. From 1st January 2015 till 1st January 2022.

Full description

In this retrospective, case-control study investigators will include all infants (0-1 year) with UTIs who were treated at Hamad General Hospital, pediatric division- PEC Doha, Qatar, using the electronic medical records from 1st January 2015 till January 1st, 2022, diagnosed by a positive urine culture. Investigators will look for the clinical manifestations, radiological and laboratory findings, renal scarring, ESBL-organisms, prevalence, median age, gender, and ethnic background. Participants are divided into two groups: early infancy and late infancy, ESBL UTIs and non-ESBL UTIs, and upper UTIs and lower UTIs. Finally, UTIs ESBL with COVID-19 and without COVID_19.

Enrollment: 5,600 patients

Sex: All

Ages: Under 1 year old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All infants with UTIs who had been treated

Exclusion criteria

• Patient with a mixed urine culture.

Trial design

5,600 participants in 4 patient groups

ESBL UTI

Description:

all infants with UTIs caused by ESBL producing organisms

Treatment:

Other: comparing, prevalence

Non-ESBL UTI

Description:

all infants with UTIs caused by non-ESBL producing organisms

Treatment:

Other: assessment

ESBL UTI with COVID-19

Description:

all infants with UTIs caused by ESBL producing organisms with COVID-19 infection

Treatment:

Other: association

ESBL UTI without COVID-19

Description:

all infants with UTIs caused by ESBL producing organisms without COVID-19 infection

Treatment:

Other: evaluation